Quantitative Pulmonary Administration of Essential Oil from Alpiniae Zerumbet Fructus for Treatment of Emphysema / 中国实验方剂学杂志

ObjectiveTo investigate the effect of quantitative pulmonary administration of the essential oil from Alpiniae Zerumbet Fructus （EOAZF） on porcine pancreatic elastase （PPE）-induced emphysema in mice and explore its action mechanism. MethodC57BL/6J mice were randomly divided into five group， namely the control group， model group， low- （2 mg·kg-1） and high-dose （20 mg·kg-1） EOFAZ groups， and positive control dexamethasone （DEX，1 mg·kg-1） group. The mice were treated with pulmonary administration of PPE using a microsprayer aerosolizer， once every seven days， for four times in total， for inducing emphysema. During this period， EOFAZ were administered with a quantitative microsprayer aerosolizer once every other day， for 14 times. The lung tissues were then sampled and stained with hematoxylin-eosin （HE） for observing the morphological changes and calculating the pulmonary mean linear intercept （MLI）. The concentrations of tumor necrosis factor-α （TNF-α）， interleukin-1β （IL-1β）， and interleukin-6 （IL-6） in the plasma were determined by enzyme-linked immunosorbent assay （ELISA）. The activities of superoxide dismutase （SOD） and catalase （CAT） and the content of malondialdehyde （MDA） in the lung tissues were measured using the biochemical assay kits. The protein expression levels of nuclear factor E2-related factor 2 （Nrf2）， quinone oxidoreductase1 （NQO1）， B cell lymphoma-2 （Bcl-2）-associated X protein （Bax）， and Bcl-2 in lung tissues were detected by Western blot. ResultThe results of lung morphological observation and MLI detection showed that compared with the control group， the model group showed obvious inflammatory infiltration， alveolar enlargement and fusion， and increased MLI （P<0.05）. Compared with the model group， EOFAZ effectively alleviated the pathological changes such as alveolar dilatation， pulmonary inflammatory cell infiltration， and lung cell apoptosis caused by PPE， and decreased the MLI （P<0.05）. As revealed by ELISA， the inflammatory level of mice in the model group increased significantly （P<0.01）， while the TNF-α， IL-1β， and IL-6 levels in the plasma were decreased after quantitative administration of EOFAZ （P<0.01）. Compared with the control group， the model group exhibited significantly enhanced oxidative stress （P<0.01）. After treatment with EOFAZ by quantitative administration， the activities of SOD and CAT in the lung tissue were increased （P<0.01） and the content of MDA was decreased （P<0.01）. Western blot results demonstrated that the apoptosis-related protein expression in the model group was increased significantly as compared with that in the control group （P<0.01）， whereas the expression levels of antioxidant stress proteins Nrf2 and NQO1 declined （P<0.05）. The relative protein expression of apoptosis-related proteins Bax/Bcl-2 in the EOFAZ groups was lower than that in the model group （P<0.01）， while the expression of antioxidant stress proteins Nrf2 and NQO1 was higher （P<0.05）. ConclusionQuantitative pulmonary administration of EOFAZ effectively alleviates the inflammation and oxidative stress， reduces lung cell apoptosis， and hinders the occurrence and development of emphysema. Its antioxidant mechanism is closely related to the up-regulation of Nrf2 and its downstream NQO1.

Preparation of berberine hydrochloride dry powder inhalation and its effect on Staphylococcus aureus pneumonia / 中草药

Objective: To prepare berberine hydrochloride dry powder inhalation, and investigate its pharmacological effect on Staphylococcus aureus pneumonia after pulmonary administration. Methods: Berberine hydrochloride dry powder by spray drying and the experimental conditions was optimized by orthogonal experiment. The lung deposition, fluidity and appearance were characterized. The pharmacodynamic effects of the preparations on S. aureus pneumonia were performed with SD rats. Results: A berberine hydrochloride dry powder was prepared at an inlet temperature of 130 ℃ with a gas volume flow of 610 L/h and a feed volume flow of 3 mL/min. The berberine hydrochloride dry powder had a lung deposition rate (FPF) of 76.4% and an aerodynamic diameter of 4.61 μm. The stability index (SI) ≈ 1, the aeration energy ratio (AR) = 1.76 > 1, and the inflation energy (AE10) = 2.1 mJ < 10 mJ. Through the pharmacodynamic evaluation of S. aureus, we can know that the berberine hydrochloride dry powder inhalation effectively improved the pathological state of pneumonia rats, and significantly reduced (P < 0.05) the number of WBC, neutrophils, and the expression of inflammatory factors (TNF-α, IL-1β, and IL-6) in pneumonia rats. Conclusion: Berberine hydrochloride dry powder inhalation can directly reach the lesion site through pulmonary administration, so it has significant therapeutic effect on S. aureus pneumonia.

Tadalafil-loaded PLGA microspheres for pulmonary administration: preparation and evaluation

Tadalafil, a long-acting PED-5 inhibitor, is commonly used for the treatment of pulmonary arterial hypertension (PAH). However, its efficacy and clinical application are severely limited by the poor water solubility, low bioavailability and a series adverse effects (e.g. headaches, indigestion). In this study, tadalafil was prepared and loaded into biodegradable PLGA (poly(lactic-co-glycolic acid)) microspheres (TDF-PLGA-MS) via emulsification-solvent evaporation. The resulting microspheres were processed into pulmonary inhalant by freeze drying. The TDF-PLGA-MS was spherical and uniform, with an average particle diameter ~10.29 µm. The encapsulation efficiency and drug loading yield of TDF-PLGA-MS were 81.68% and 8.52%, respectively. The investigation of micromeritics showed that the TDF-PLGA-MS had low moisture content. The fluidity of powders was relatively good. The aerodynamic diameter and emptying rate of microspheres powders were 3.92 µm and 95.41%, respectively. Therefore, the microspheres powders were easy to be atomized, and can meet the requirements of pulmonary administration. In vitro release results showed that the microspheres group released slowly. The cumulative release in 24 h and 10 d was 46.87% and 84.06%, respectively. The in vitro release profile of TDF-PLGA-MS was in accordance with the Weibull model. The results of Pharmacokinetics showed that tadalafil from microspheres slowly released into the blood after intratracheal instillation. The pulmonary drug residue in 0.5 h was 3.5 times compared with solution group. The residual concentration in lung after 10d was still higher than that of solution group in 48 h. The t1/2β and MRT0-∞ were 3.10 times and 3.96 times that of solution group, respectively. Moreover, the Cmax and AUC of drug residues in lung ​​were 3.48 times and 16.36 times that of solution group, respectively. The results of tissue distribution showed that the Re in lung was 16.358, which indicated the lung targeting. In conclusion, the TDF-PLGA-MS for pulmonary administration in this study can significantly improve the pulmonary targeting, increase efficacy of tadalafil and reduce other non-target organs toxicity. This study will have an important clinical significance for PAH patients who need long-term drug therapy.

Research Progress in New Dosage Forms of Anti-tumor Drugs for Pulmonary Administration / 中国药师

Lung cancer is one of the most common malignancies. Anti-tumor drugs with intravenous administration have systemic adverse effects as well as limited efficacy. Drugs can concentrate in lungs after pulmonary administration,which limits the distribution in the other organs and reduces the side effects of anti-tumor drugs. The paper focused on the recent progress in the studies on new dos-age forms of anti-tumor drugs for pulmonary administration for the therapy of lung cancer,so as to provide reference for the development of anti-tumor drugs for pulmonary administration.

Preparation of dry powder inhalation of yuanhuacine and its tissue distribution in rats / 中国药科大学学报

The aim of the present study was to increase distribution of yuanhuacine in the lungs and achieve the purpose of reducing toxicity and increasing efficiency.Therefore,yuanhuacine was designed to be dry powder inhalers innovatively and directly delivered to the lungs.Accordingly,inhaled lactose was used as a carrier to adsorb yuanhuacine on the surface of lactose.Fine particle fraction (FPF) was utilized as evaluation index to filtrate the optimal prescription for pulmonary administration.Besides,an UHPLC-MS/MS method was established for the analysis of heart,liver,spleen,lung,kidney,brain and reproductive system of rats.Intravenous injection was taken as reference to investigate the distribution of yuanhuacine and calculate relevant targeting parameters.The experimental result indicated that the prescription (rough lactose ∶fine lactose =10 ∶ 1) has the highest FPF,which can be chosen as the most suitable prescription for pulmonary administration of yuanhuacine.Moreover,by comparing the distribution of yuanhuacine through pulmonary administration and intravenous injection,it was found that the concentration of yuanhuacine in the lung tissue was greatly increased by pulmonary administration,which decreased the distribution in heart,liver,spleen,kidney,brain and reproductive system,thus sequentially reducing the toxicity in other tissues and increased the efficiency.

Research Progress in Bioavailability Improvement Methods for Curcumin / 中国药师

Curcumin is the main active component in turmeric, which possesses many pharmacologic effects, including anti-in-flammatory, antioxidant, anti-tumor, anti-atherosclerosis, liver and kidney protection and so on. However, due to its poor bioavail-ability, its clinical application is limited. Therefore, the methods for improving the bioavailability of curcumin were reviewed by refer-ring to a large number of literatures. The bioavailability of curcumin can be improved by different administration routes and various dos-age forms. The review provides theoretical basis and research ideas for the development of new drugs.

Nanocristais de furosemida: preparação, caracterização físico-química e avaliação in silico de absorção oral e pulmonar / Furosemide nanocrystals: preparation, physical-chemical characterization and in silico evaluation of oral and lung absorption

Segundo a Organização Mundial de Saúde, a hipertensão arterial é responsável por uma crise global de saúde pública, sendo as doenças cardiovasculares implicadas em aproximadamente 17 milhões de mortes/ano, das quais, 9,4 milhões ocasionadas por complicações provocadas pela hipertensão, como edema pulmonar. Quanto ao arsenal terapêutico disponível, a furosemida, potente diurético de alça, é amplamente utilizada em situações de controle e emergência relacionadas à hipertensão e ao edema pulmonar cardiogênico. Apesar do elevado índice de sua prescrição, esse fármaco pertence à classe IV do Sistema de Classificação Biofarmacêutica (SCB), apresentando absorções intestinais erráticas e variáveis. Tais características representam desafio para o desenvolvimento de formas farmacêuticas orais. Assim, adoção de tecnologias inovadoras associadas à via de administração pulmonar pode permitir abordagem terapêutica alternativa, com elevado potencial de aplicação. Entre as tecnologias inovadoras, a obtenção de nanocristais de fármacos classes II e IV tem sido promissora. Nanocristais podem exibir desempenho in vivo superior quando comparados aos seus homólogos, na forma micronizada. Portanto, estratégias que permitam o desenvolvimento de medicamentos contendo furosemida, com maior eficácia e segurança, são de fundamental importância. Nesse sentido, a aplicação de tecnologia in silico, com propriedade preditiva, contribui para a racionalização de ensaios na pesquisa e no desenvolvimento de novas formas farmacêuticas. Objetivou-se, desse modo, a preparação e a caracterização físico-química de nanocristais de furosemida e sua avaliação in silico na absorção oral e pulmonar empregando ferramenta computacional. Os nanocristais foram obtidos por moagem à alta energia, utilizando movimentos simultâneos de revolução/rotação. A determinação da distribuição do tamanho e a morfologia foram realizadas por difração de raios laser e microscopia eletrônica de varredura, respectivamente. As possíveis interações e/ou alterações do estado cristalino do fármaco foram investigadas por calorimetria exploratória diferencial, termogravimetria diferencial, difração de raio X e espectroscopia Raman de baixo deslocamento. Quanto à solubilidade do nanocristal, foram realizados ensaios para a determinação do aumento na solubilidade de equilíbrio e da velocidade dissolução, utilizando os métodos shake flask e velocidade de dissolução intrínseca (VDI), respectivamente. A moagem à alta energia permitiu a obtenção de nanocristais com tamanho médio trinta vezes menor (231nm) do que o tamanho inicial, na escala micrométrica (7,1 µm). Os nanocristais apresentaram estabilidade térmica. Não foram observadas interações entre os excipientes e os nanocristais, que, entretanto, exibiram estrutura cristalina menos definida, o que indica parcial amorfização do nanocristal. A solubilidade de saturação dos nanocristais aumentou aproximadamente três vezes; como consequência, houve aumento na VDI em 2,2 vezes, 1,8 vezes e 3,8 vezes, quando comparado à VDI da furosemida micronizada em meio SGF, tampão 4,5 e SIF, respectivamente. Quanto às avaliações in silico dos nanocristais, sua absorção oral revelou moderada alteração no perfil farmacocinético. Quando foi utilizada a via de administração pulmonar, os nanocristais apresentaram maior desempenho quando comparada a via de administração oral; destacando-se o aumento na Fa% e na Cmáx e a acentuada diminuição no Tmáx. Em conclusão, a plataforma tecnológica obtida tem potencial aplicação no desenvolvimento de formas farmacêuticas inovadoras para administração pulmonar de furosemida

According to the World Health Organization, hypertension is responsible for global public health crisis, being the cardiovascular diseases involved in approximately 17 million deaths a year, of these, 9.4 million occasioned by hypertension complications such as pulmonary edema. Regarding therapeutic arsenal available, Furosemide is a potent loop diuretic widely used in control and emergency situations related to hypertension and cardiogenic pulmonary edema. Despite the high level of prescribing, this drug belongs a class IV drug, according to Biopharmaceutics Classification System (BCS), exposing erratic and variable intestinal absorption. These characteristics represent a challenge for the development of oral dosage forms. Thus, adoption of innovative technologies associated with pulmonary route of administration may allow an alternative therapeutic approach, with high potential for application. Among the new technologies, those for obtaining nanocrystals of classes II and IV drugs have been a promising approach. Nanocrystals can exhibit in vivo higher performance when compared to their counterparts in micronized form. Therefore, strategies to develop medicines containing Furosemide, with greater efficacy and safety, are of critical importance. In this sense, the application of technology in silico, with predictive property, contributes to the rationalization of testing in research and development of new dosage forms. The objectives, as a result, were the preparation and the physicochemical characterization of Furosemide nanocrystals, and it's in silico evaluation on oral and pulmonary absorption using a computational tool. The nanocrystals were obtained using a high-energy milling technology under simultaneous revolution/rotation motion. The determination of the size distribution and morphology was performed using laser diffraction and scanning electron microscopy, respectively. Furthermore, differential scanning calorimetry, differential thermogravimetry, X-ray diffraction and Low Shift Raman spectroscopy were performed to investigate possible interactions and changes in the crystalline state of the nanocrystals. To measure the increase in the equilibrium solubility and dissolution rate, the shake flask and intrinsic dissolution rate (IDR) methods were used respectively. The nanocrystals size appeared thirty times lower (231 nm) compared to the initial size (7,1 µm). The nanocrystals were stable with concern to its thermal characteristic not showing interactions between the excipients and the nanocrystals; however, they exhibited less defined crystal structure, indicating partial amorphization. The nanocrystals saturation solubility increased approximately three times. Consequently, 2.2, 1.8 and 3.8 folds increase were observed in IDR when compared to the Furosemide raw material in SGF, buffer 4.5 and SIF, respectively. The in silico nanocrystal studies revealed moderate changes in its oral absorption and pharmacokinetic profile. When the pulmonary route of administration was used, the nanocrystals showed higher performance compared to oral route administration; highlighting the increase in Fa % and Cmax and a significant decrease in Tmax. In conclusion, the technology platform obtained has potential application in the development of innovative dosage forms for Furosemide pulmonary delivery